Recently, immune checkpoint blockade, particularly using mAbs targeting PD-L1, PD-1, or CTLA-4 has achieved outstanding therapeutic efficacy for patients with metastatic melanoma, NSCLC, microsatellite stable colorectal cancer, and other tumor types. Here, CTLA4 is linked to neoplasm.